SCHEMBL26536748

SCHEMBL26536748

O=S(=O)(Nc1cccc(O)c1)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.62
UQCRB P14927 1/20 0.61
FFAR4 Q5NUL3 2/20 0.58
NLRP3 Q96P20 1/20 0.55
KMT2A Q03164 1/20 0.54
CYP19A1 P11511 1/20 0.54
HDAC1 Q13547 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
TCF4 P15884 1/20 0.51
CTNNB1 P35222 1/20 0.51
GPR119 Q8TDV5 1/20 0.51
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14458175 0.84 ALOX15 (0.64) FFAR4KMT2ACYP19A1HDAC1GPR119
SCHEMBL31681329 0.84 FFAR4 (0.65) FFAR4KMT2ACYP19A1HDAC1HDAC8
SCHEMBL18031172 0.83 HDAC1 (0.63) UQCRBFFAR4HDAC1HDAC8HDAC3
SCHEMBL7572608 0.83 KMT2A (0.61) FFAR4KMT2AHDAC1HDAC8HDAC3
SCHEMBL6296943 0.82 CYP19A1 (0.80) HSD17B2UQCRBFFAR4KMT2ACYP19A1
SCHEMBL1592342 0.81 HSD17B2 (0.79) HSD17B2UQCRBFFAR4KMT2ACYP19A1
SCHEMBL28561814 0.81 FFAR4 (0.61) FFAR4KMT2ACYP19A1HDAC1TCF4
SCHEMBL4650259 0.81 GPR119 (0.61) FFAR4CYP19A1HDAC1HDAC8TCF4
SCHEMBL10093399 0.80 POLB (0.74) FFAR4KMT2AHDAC1HDAC8TCF4
SCHEMBL7175051 0.80 HSD17B2 (0.72) HSD17B2UQCRBKMT2ACYP19A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 HSD17B2 4681/4885UQCRB 4135/4885FFAR4 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.